Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada
Knowles, S.R., Phillips, E.J., Dresser, L. and Matukas, L. (2003) Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada. Clinical Infectious Diseases, 37 (8). pp. 1139-1142.
*Subscription may be required
Although information on efficacy and adverse drug reactions is lacking, ribavirin has been used empirically for the treatment of severe acute respiratory syndrome (SARS). We report common adverse events in 110 patients with suspected or probable SARS who were treated with ribavirin. Sixty-one percent of the patients had evidence of hemolytic anemia, and hypocalcemia and hypomagnesmia were reported in 58% and 46% of patients, respectively.
|Publication Type:||Journal Article|
|Publisher:||University of Chicago Press|
|Copyright:||© 2003 by the Infectious Diseases Society of America|
|Item Control Page|
Downloads per month over past year